검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | combination (Trastuzumab plus Pertuzumab, Trastuzumab plus Pertuzumab (combination)) Roche / Genentech·Cancer ORR 88.6% |
|---|---|
Overview Program | Trastuzumab plus Pertuzumab (combination) |
Overview Company | Roche / Genentech |
Overview Modality | ANTIBODY |
Overview Target | Cancer |
Overview Indication | Cancer; Tumors |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | of ProAgio, which includes reducing hypoxia and modulating TME |
MoA Biomarker | biomarkers and sex hormone receptor profiles in assessing post-surgical prognosis among HCC patients |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Benefits and challenges of adding BKM120 to a BI-3406 plus trametinib combination therapy.. Achieving a balance between efficacy and side effects is essential for the success of new combinatorial cancer therapies. This study investigated the impact of adding BKM120, a PI3K inhibitor, to a dual regimen consisting of BI-3406, a KRAS/SOS1 inhibitor, and trametinib, a MEK inhibitor. The therapeutic ef… |
Clinical Primary efficacy | ORR 88.6% |
Clinical ORR | 88.6% |
Clinical OS | 99.54 |
Clinical Result source | ClinicalTrials.gov NCT02586025 |
Clinical Data Tier / Score | A · 66 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 4일 (9일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | combination (Trastuzumab plus Pertuzumab, Trastuzumab plus Pertuzumab (combination)) Roche / Genentech·Cancer ORR 88.6% |
|---|---|
Overview Program | Trastuzumab plus Pertuzumab (combination) |
Overview Company | Roche / Genentech |
Overview Modality | ANTIBODY |
Overview Target | Cancer |
Overview Indication | Cancer; Tumors |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | of ProAgio, which includes reducing hypoxia and modulating TME |
MoA Biomarker | biomarkers and sex hormone receptor profiles in assessing post-surgical prognosis among HCC patients |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Benefits and challenges of adding BKM120 to a BI-3406 plus trametinib combination therapy.. Achieving a balance between efficacy and side effects is essential for the success of new combinatorial cancer therapies. This study investigated the impact of adding BKM120, a PI3K inhibitor, to a dual regimen consisting of BI-3406, a KRAS/SOS1 inhibitor, and trametinib, a MEK inhibitor. The therapeutic ef… |
Clinical Primary efficacy | ORR 88.6% |
Clinical ORR | 88.6% |
Clinical OS | 99.54 |
Clinical Result source | ClinicalTrials.gov NCT02586025 |
Clinical Data Tier / Score | A · 66 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 4일 (9일 전) |
추천 비교
추천 비교